Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell the Rare Pediatric Disease Priority Review Voucher for US$150 million.
The company said the transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
The US FDA granted the voucher following the approval of DAYBUE (trofinetide) for the treatment of Rett syndrome.
Under the license agreement between Acadia and Neuren, Neuren is entitled to receive one-third of the proceeds, net of any applicable costs, which are not expected to be material.